Matt offers 12 years of industry experience including the application of modeling and simulation for clinical pharmacology and later phase drug development decisions. Matt’s interests include the development and application of mechanistic exposure-response and systems pharmacology models to quantitatively integrate physiology, pharmacology, senescence and disease understandings; this to guide translational and clinical research toward improved preventative and interventional therapeutics.
Rena J. Eudy, William R. Gillespie, Matthew M. Riggs, Marc R. Gastonguay. Linking a Mechanistic Model of Bone Mineral Density to a Time-To-Event Model of Fracture. ACoP 6. October 2015.
RJ Eudy, MR Gastonguay, KT Baron, and MM Riggs.Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model. CPT Pharmacometrics Syst. Pharmacol. 2015 Sep; 4(9): 527-536.
Eudy RJ, Gastonguay MR, Baron KT, Riggs MM. Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis. PAGE 24 (2015) Abstr 3355
Alanna S. Ocampo-Pellend, Marc R. Gastonguay, Jonathan L. French, Matthew M. Riggs. Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D3 and its 25OHD3 Metabolite. PAGE 2015.
Peterson, MC and Riggs, MM. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? CPT: Pharmacometrics & Systems Pharmacology, 2015 Mar; 4(3).
Alanna S. Ocampo-Pelland, Marc R. Gastonguay, Joseph A. Lorenzo, and Matthew M. Riggs. Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D. ASBMR 2014 Annual Meeting.
M. M. Riggs, L. J. Seman, A. Staab, T. R. MacGregor, W. Gillespie, M. R. Gastonguay, H. J. Woerle, and S. Macha. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (sglt2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol, Jun 2014.
An Evaluation of Calcilytic Effects on Parathyroid Hormone and Bone Mineral Density Response Using a Physiologically-Based, Multiscale Systems Pharmacology Model. Kyle T. Baron, Matthew M. Riggs, Ryoko Sawamura, Takako Shimizu, Fumihiko Okada, Jin Zhou, Takahiro Shibayama, Mendel Jansen. Published at ASBMR in October, 2013.
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Riggs MM, Staab A, Seman L, Macgregor TR, Bergsma TT, Gastonguay MR, Macha S. J Clin Pharmacol. 2013 Aug 13.
S. Olson, K. Baron, M. Riggs, W. O. Böcher, and F. J. Mensa. 1212 pharmacokinetic modelling of the relationship between sustained virological response and plasma concentrations of faldaprevir or bi-207127 in hcv gt1-infected patients in sound-c2. Journal of Hepatology, 58:S492–S493.
Matthew Riggs. Systems Pharmacology Model Development to Provide Physiologically-Based Interpretation and Drug Development Decision Support in Osteoporosis and Other Bone-Related Diseases. ASCPT 2013.
Riggs MM. Extensions of a Multiscale Systems Pharmacology Model of Bone Mineral Balance and its Regulation of Bone Health. Presented at Sunrise Session INTEGRATION OF SYSTEMS MODELING IN CLINICAL DEVELOPMENT: SUCCESSES, CHALLENGES, AND FUTURE OUTLOOK of The American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Indianapolis, Indiana; March 7, 2013
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2013 Jan;109(1):77-85.
Peterson, MC and Riggs, MM. Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model. CPT: pharmacomet. syst. pharmacol. 2012 Nov online;1(e14).
M M Riggs, M Bennetts, P H van der Graaf, and S W Martin. Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis. CPT: Pharmacometrics & Systems Pharmacology. Published online, 2012.
Matthew M. Riggs, Kyle T. Baron, Elodie L. Plan, Marc R. Gastonguay. Qualification of a Physiologically-Based Model for Predicted Bone Marker and Bone Mineral Density Changes Associated with Denosumab Treatment. Presented at American Society of Bone Mineral Research (ASBMR) Annual Meeting, Minneapolis, MN; October 14, 2012 (Abstract# SU0363).
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2012 Sep 28.
Elodie L. Plan, Kyle T. Baron, Marc R. Gastonguay, Jonathan L. French, William R. Gillespie, and Matthew M. Riggs. Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension. PAGE 21 (2012) Abstr 2592.
Riggs MM. Systematic Extension of a Physiologic Model of Bone and Calcium Homeostasis. Presented at 2012 AAPS National Biotechnology Conference, Symposium on Advancements and Applications of Multiscale Systems Pharmacology (MSP) Modeling (#144). San Diego, CA; May 22, 2012.
M. M. Riggs, T. T. Bergsma, J. A. Rogers, M. R. Gastonguay, G. M. Subramanian, C. Chen, M. Devalaraja, A. E. Corey, H. Sun, J. Yu, and D. S. Stein. Population pharmacokinetics and exposure-response of albinterferon alfa-2b. J Clin Pharmacol, 52(4):475–86, Apr 2012.
Riggs MM, Peterson MC, Gastonguay MR. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J Clin Pharmacol. 2012 Jan;52(1 Suppl):45S-53S.
Riggs MM. Applying a Multiscale Physiologic System Model to Evaluate Bone-Related Disease and Therapeutic Responses. Presented at First Indiana Clinical and Translational Sciences Institute (CTSI) Symposium on Disease and Therapeutic Response Modeling. Indiana University – Purdue University Indianapolis; Indianapolis, IN; 03-Nov-2011
Kyle T. Baron, Patanjali Ravva, Vivek Purohit, Matthew M. Riggs, Marc R. Gastonguay. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 2011.
Riggs MM, Bennetts M, Martin SW, Van Der Graaf PH. Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis. Presented at ACOP 2011, San Diego, CA.
Riggs MM. A Physiologically-Based, Multi-Scale, Mathematical Model of Integrated Calcium Homeostasis and Bone Remodeling. Presented at ACOP 2011, San Diego, CA.
Bergsma T, Fisher J, Gastonguay MR, Hane J, Knebel W, Riggs MM, Rogers JA. Systematic Review of Versioned Files for Modeling and Simulation Quality Control: The“review” R Package. Presented at ACOP 2011, San Diego, CA.
Baron K, Ravva P, Purohit V, Riggs MM, Gastonguay MR. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. Presented at ACOP 2011, San Diego, CA.
Riggs MM, Gastonguay MR, Peterson MC. A physiologically-based, multiscale model used to predict progressive bone mineral density loss due to chronic renal disease. Presented at 2010 American Association of Pharmaceutical Scientists (AAPS) Annula Meeting, New Orleans LA; November 17, 2010; Poster # W4403
Riggs MM. Development of Mechanistic/Multiscale/Systems Biology Models in Clinical Pharmacology and Translational Research: Do the Challenges Outweigh the Potential Benefits? 2010 AAPS Clinical Pharmacology and Translational Research (CPTR) Open Forum; November 16, 2010.
Riggs MM, Gillespie WR, Gastonguay MR, Peterson MC. Extension of a Multiscale Model of Calcium Homeostasis and Bone Remodeling to Include the Progressive Effects of Estrogen Loss During Menopause Transition. Presented at National Institute of General Medical Sciences Quantitative Systems Pharmacology Workshop II. Bethesda, MD; September 9, 2010.
Riggs MM. Multiscale Modeling: The Quantitative Integration of Systems Biology, Clinical Pharmacology and Translational Research. Presented at American Association of Pharmaceutical Scientists National Biotechnology Conference, Update on Quantitative Systems and Disease Models for Biologics. Mini–Symposium. San Francisco, CA; May 2010.
Peterson MC and Riggs MM. Predicting Nonlinear Changes in BMD Over Time using a Physiologically-Based Mathematical Model. Presented at American Association of Pharmaceutical Scientists National Biotechnology Conference, Update on Quantitative Systems and Disease Models for Biologics. Mini–Symposium. San Francisco, CA; May 2010.
Nathanael Dirks, Marc R. Gastonguay, William R. Gillespie, William Knebel, Matthew M. Riggs, John C. Panetta, and Bernd Meibohm. Comparative Performance of Bayesian Markov Chain Monte Carlo and Maximum Likelihood Population Estimation Methods when Applied to Nonlinear Pharmacokinetics of Monoclonal Antibodies. Presented at ASCPT 111th Annual Meeting, March 17-20, 2010
Peterson MC, Riggs MM. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone. 2010 Jan; 46: 49-63.
James A. Rogers, Matthew M. Riggs, Monte Cofﬁner, William R. Gillespie, Robert Burford, Francis Vanderbist, Sophie De Niet, Marc R. Gastonguay. Clinical Trial Simulation to Compare Adaptive and Fixed Designs for a Phase 3 Clinical Trial of Nacystelyn® (L-Lysine-N-acetyl-L-cysteinate) for Cystic Fibrosis. ACOP 2009.
Riggs MM, Peterson MC, Gastonguay MR. A Systems Biology Model to Describe Long-Term Bone Remodeling Effects of Estrogen in Menopausal and Postmenopausal Women.
Riggs MM, Bergsma TT, Gillespie WR, Gastonguay MR, Sprenger KJ. Use of Rpad, an Open-Source, Interactive, Web-Based Analysis Program, for Visualization During Model-Based Drug Development of Adipiplon, a GABAA Receptor Partial Agonist Under Investigation for the Treatment of Insomnia. American Conference on Pharmacometrics, 2008.
Knebel W, Bergsma T, Fisher J, Georgalis G, Gibiansky L, Gillespie WR, Riggs MM, and Gastonguay MR. Facilitating the Pharmacometrics Work-Flow with the MItools R Package. American Conference on Pharmacometrics, 2008.
Riggs M. Exposure-response (PK-PD) applied to model-based drug development: A case study of Drug X. FDA/Industry Statistics Workshop (2006) Parallel Session 14: Case Studies in Modeling and Simulation, Abstract.